MADISON — A Mississippi-based pharmaceutical company has agreed to pay $2.8 million to resolve civil allegations that the manufacturer falsely marketed skin products to receive government funding.
U.S. Attorney John M. Bales said yesterday Cypress Pharmaceutical Inc., a subsidiary and CEO Max Draughn will pay $1.6 million to the military’s TRICARE program and $1.2 million to state Medicaid programs.
The government alleges that Cypress subsidiary Hawthorne Pharmaceuticals Inc. claimed that three skin products carried the Food and Drug Administration’s “safe and effective” designation when the treatments didn’t. The government also claims the regulatory status of the products was misrepresented.
Bales says a whistleblower who sued under the False Claims Act received $300,000 as part of the settlement.
An official for Madison-based Cypress didn’t immediately return a phone call seeking comment.
BEFORE YOU GO…
… we’d like to ask for your support. More people are reading the Mississippi Business Journal than ever before, but advertising revenues for all conventional media are falling fast. Unlike many, we do not use a pay wall, because we want to continue providing Mississippi’s most comprehensive business news each and every day. But that takes time, money and hard work. We do it because it is important to us … and equally important to you, if you value the flow of trustworthy news and information which have always kept America strong and free for more than 200 years.
If those who read our content will help fund it, we can continue to bring you the very best in news and information. Please consider joining us as a valued member, or if you prefer, make a one-time contribution.Click for more info